2. Cell Cycle/DNA Damage Metabolic Enzyme/Protease NF-κB MAPK/ERK Pathway PI3K/Akt/mTOR Autophagy Immunology/Inflammation Protein Tyrosine Kinase/RTK
  3. HSP NF-κB p38 MAPK Akt Autophagy Interleukin Related VEGFR
  4. Tubeimoside I

Tubeimoside I  (Synonyms: Tubeimoside-1; Lobatoside-H)

Cat. No.: HY-N0890 Purity: 99.96%
SDS
COA
Handling Instructions Technical Support

Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases.

For research use only. We do not sell to patients.

Tubeimoside I Chemical Structure

Tubeimoside I Chemical Structure

CAS No. : 102040-03-9

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Tubeimoside I:

Tubeimoside I Related Antibodies

Top Publications Citing Use of Products

View All HSP Isoform Specific Products:

View All Isoforms
HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases[1][2][3][4][5][6][7][8][9][10][11].

In Vitro

Tubeimoside I (0.5-8 µM; 6-48 h) induces cytoprotective autophagy in human breast cancer cells (MDA-MB-231, MCF-7, T47D) via Akt-mediated pathway[1].
Tubeimoside I (20 µM; 24 h) inhibits the late stage of autophagic flux in lung cancer cells transfected with mCherry-GFP-LC3 tandem plasmids[2].
Tubeimoside I (0-30 µM; 24 h) markedly decreases cervical cancer (Hela and SiHa) cell viability in a dose-dependent manner[3].
Tubeimoside I (25 μM; 4-24 h) causes cell cycle arrest at the G2/M phase in HeLa cells in a dose- and time- dependent manner[4].
Tubeimoside I (3-15 μM; 12-24 h) induces oxidative stress-mediated apoptosis and G0/G1 phase arrest in human prostate carcinoma cells DU145 and PC3[5].
Tubeimoside I (15-30 μM; 24 h) induces apoptosis in HepG2 and L-02 cells[6].
Tubeimoside I (2-6 μM; 1 h) attenuates LPS-induced inflammation in RAW 264.7 cells, inhibiting the production of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β[7].
Tubeimoside I (0.5-10 μM; 48 h) inhibits the viability of HCT-116 colon cancer cells in a dose-dependent manner[10].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tubeimoside I Related Antibodies

Apoptosis Analysis[1]

Cell Line: MCF-7, MDA-MB-231, T47D
Concentration: 0.5 μM, 1 μM, 2 μM, 4 μM, 8 μM
Incubation Time: 6, 9, 12, 24, 36 h
Result: Induced apoptosis in a dose-dependent manner, as determined by increased cleaved PARP and caspase-3 levels.
Decreased the levels of Mcl-1, Bcl-xl, and Bcl-2 in a time- and dose- dependent manner.
In Vivo

Tubeimoside I (1-4 mg/kg; i.p.; 13 days) inhibits the growth of tumors in nude mice subcutaneously inoculated with NCI-H1299 cells in a dose-dependent manner and does not cause a decrease in the body weight of the mice[2].
Tubeimoside I (3 mg/kg; i.p.; daily; 16 days) inhibits the growth of HeLa-xenografted tumors in nude mice, as indicated by smaller tumor size, volume, and mass[3].
Tubeimoside I (1-4 mg/kg; i.p.; 1 h before LPS challenge) reduces lung injury, down-regulates the secretion of TNF-α, IL-6 and IL-1β, and inhibits the activation of NF-κB and MAPK in a murine model of LPS-induced acute lung injury[7].
Tubeimoside I (45-180 mg/kg; p.o.; daily; 21 consecutive days) attenuates inflammation and oxidative damage in a mice model of PM2.5‑induced pulmonary injury[8].
Tubeimoside I (4 mg/kg; i.p.; 1 h before cecal ligation and puncture (CLP)) improves survival of mice in sepsis by inhibiting inducible nitric oxide synthase expression[9].
Tubeimoside I (4 mg/kg; i.p.; every day; 28 days) improves recovery from hindlimb ischemia and increases capillary density in C57BL/6 mice[11].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 5-week-old male BALB/c nude mice (weighing 18-22 g), lung cancer xenograft model established by subcutaneous injection of NCI-H1299 cells[2]
Dosage: 1 mg/kg, 4 mg/kg
Administration: Intraperitoneal injection, 13 days
Result: Reduced the tumor volume and weight.
Significantly upregulated the expression levels of cleaved-PARP, cleaved-caspase 3, LC3-II, and p62 in the tumor tissues.
Animal Model: Female BALB/c nude mice (4-week-old) with HeLa cell xenograft model[3]
Dosage: 3 mg/kg
Administration: Intraperitoneal injection, daily, for 16 days
Result: Decreased the expression of Ki67 in tumor tissues, indicating reduced proliferating ability.
Induced tumor cell apoptosis, as evidenced by the accumulation of cleaved-CASP3 and cleaved-PARP1 in tumor tissues.
Induced autophagosome accumulation in tumor cells, with increased LC3 II expression and enhanced LC3 staining in tumor tissues.
Molecular Weight

1319.43

Formula

C63H98O29
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@@]12C([C@@]3([H])[C@](C(O[C@@H]4OC[C@H](O)[C@H](O)[C@H]4O[C@@H]5O[C@@H](C)[C@H](OC(C[C@](O)(C)CC6=O)=O)[C@@H](O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O)[C@H]5O)=O)(CCC(C)(C)C3)CC2)=CC[C@@]8([H])[C@@]1(C)CC[C@]([C@](C)(CO)[C@H]9O[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10O[C@@H]%11OC[C@H](O6)[C@H](O)[C@H]%11O)([H])[C@]8(C)C[C@@H]9O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (75.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.7579 mL 3.7895 mL 7.5790 mL
5 mM 0.1516 mL 0.7579 mL 1.5158 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (1.89 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (1.89 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.96%

SDS (393 KB)

COA (267 KB) HNMR (268 KB) RP-HPLC (192 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 0.7579 mL 3.7895 mL 7.5790 mL 18.9476 mL
5 mM 0.1516 mL 0.7579 mL 1.5158 mL 3.7895 mL
10 mM 0.0758 mL 0.3790 mL 0.7579 mL 1.8948 mL
15 mM 0.0505 mL 0.2526 mL 0.5053 mL 1.2632 mL
20 mM 0.0379 mL 0.1895 mL 0.3790 mL 0.9474 mL
25 mM 0.0303 mL 0.1516 mL 0.3032 mL 0.7579 mL
30 mM 0.0253 mL 0.1263 mL 0.2526 mL 0.6316 mL
40 mM 0.0189 mL 0.0947 mL 0.1895 mL 0.4737 mL
50 mM 0.0152 mL 0.0758 mL 0.1516 mL 0.3790 mL
60 mM 0.0126 mL 0.0632 mL 0.1263 mL 0.3158 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tubeimoside I Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tubeimoside I102040-03-9Tubeimoside-1 Lobatoside-HTubeimoside1Tubeimoside 1HSPNF-κBp38 MAPKAktAutophagyInterleukin RelatedVEGFRHeat shock proteinsNuclear factor-κBNuclear factor-kappaBPKBProtein kinase BILVascular endothelial growth factor receptorHCT-116 RAW 264.7HeLaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tubeimoside I
Cat. No.:
HY-N0890
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.